Abstract CT225: A Phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer
Year: 2019
Type: conference-abstract
Source: Clinical Trials
Authors: Karen L. Reckamp, Wallace Akerley, Martin J. Edelman, Balazs Halmos, Kai He, Melissa Johnson, Raja Mudad, Joel W. Neal, Taofeek K. Owonikoko, Jyoti D. Patel, Sandip P. Patel, Jonathan W. Riess, Adrian G. Sacher, Simon Turcotte, Liza C. Villaruz, Marjorie G. Zauderer, Benedetto Farsaci, Aisha Hasan, Roma Patel, Yuehui Wu, Michael Chisamore, Vincent Lam
Institutions: City Of Hope National Medical Center, Huntsman Cancer Institute, Fox Chase Cancer Center, Albert Einstein College of Medicine, Montefiore Medical Center, The Ohio State University Wexner Medical Center, Sarah Cannon, Tennessee Oncology, University of Miami, Sylvester Comprehensive Cancer Center, Stanford Cancer Institute, Stanford University, Winship Cancer Institute, University of Chicago, Moores Cancer Center, UC Davis Comprehensive Cancer Center, Princess Margaret Cancer Centre, Centre Hospitalier de l’Université de Montréal, UPMC Hillman Cancer Center, Memorial Sloan Kettering Cancer Center, GlaxoSmithKline (United States), GlaxoSmithKline (United Kingdom), Merck & Co., Inc., Rahway, NJ, USA (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4237983179